Response to letter re: Benefit from maintenance with PARP inhibitor in newly diagnosed ovarian cancer according to BRCA1/2 mutation type and site: a multicenter real-world study.
作者信息
Marchetti C, Fagotti A, Fruscio R, Cassani C, Incorvaia L, Perri M T, Sassu C M, Camnasio C A, Giudice E, Minucci A, Seca M, Arbustini E, Vertechy L, De Bonis M, Boccia S M, Giannarelli D, Salutari V, Distefano M, Ferrandina M G, Nero C, Musacchio L, Russo A, Scambia G, Lorusso D
机构信息
Department of Women, Children and Public Health Sciences, Fondazione Policlinico Universitario Agostino Gemelli, IRCCS, Rome, Italy; Department of Health Science and Public Health, Catholic University of the Sacred Heart, Rome, Italy.
Department of Women, Children and Public Health Sciences, Fondazione Policlinico Universitario Agostino Gemelli, IRCCS, Rome, Italy; Department of Health Science and Public Health, Catholic University of the Sacred Heart, Rome, Italy.
出版信息
ESMO Open. 2025 Jun;10(6):105289. doi: 10.1016/j.esmoop.2025.105289. Epub 2025 May 29.
Abstract
摘要
相似文献
1
Response to letter re: Benefit from maintenance with PARP inhibitor in newly diagnosed ovarian cancer according to BRCA1/2 mutation type and site: a multicenter real-world study.对关于“根据BRCA1/2突变类型和位点，PARP抑制剂维持治疗对新诊断卵巢癌的获益：一项多中心真实世界研究”信件的回复
ESMO Open. 2025 Jun;10(6):105289. doi: 10.1016/j.esmoop.2025.105289. Epub 2025 May 29.
2
Letter re: Benefit from maintenance with PARP inhibitor in newly diagnosed ovarian cancer according to BRCA1/2 mutation type and site: a multicenter real-world study: Ethnic difference in BRCT domain response to PARP inhibitor.信件回复：根据BRCA1/2突变类型和位点，新诊断卵巢癌患者使用PARP抑制剂维持治疗的获益：一项多中心真实世界研究：BRCT结构域对PARP抑制剂反应的种族差异
ESMO Open. 2025 Jun;10(6):105288. doi: 10.1016/j.esmoop.2025.105288. Epub 2025 May 27.
3
Response to letter re: Benefit from maintenance with PARP inhibitor in newly diagnosed ovarian cancer according to BRCA1/2 mutation type and site: a multicenter real-world study: Not all BRCA mutations are equal: functional context and mutation type as co-determinants of PARP inhibitor response.对关于“根据BRCA1/2突变类型和位点，新诊断卵巢癌患者使用PARP抑制剂维持治疗的获益：一项多中心真实世界研究：并非所有BRCA突变都相同：功能背景和突变类型作为PARP抑制剂反应的共同决定因素”的信件的回复
ESMO Open. 2025 Jun;10(6):105299. doi: 10.1016/j.esmoop.2025.105299. Epub 2025 May 29.
4
Letter Re: Benefit from maintenance with PARP inhibitor in newly diagnosed ovarian cancer according To BRCA1/2 mutation type and site: a multicenter real-world study: Not all BRCA mutations are equal: functional context and mutation type as co-determinants of PARP inhibitor.信件回复：根据BRCA1/2突变类型和位点，新诊断卵巢癌患者使用PARP抑制剂维持治疗的获益：一项多中心真实世界研究：并非所有BRCA突变都是等同的：功能背景和突变类型作为PARP抑制剂的共同决定因素
ESMO Open. 2025 Jun;10(6):105298. doi: 10.1016/j.esmoop.2025.105298. Epub 2025 May 29.
5
Poly (adenosine diphosphate [ADP]-ribose) polymerase (PARP) inhibitors as maintenance therapy in women with newly diagnosed ovarian cancer: a systematic review and meta-analysis.聚（腺苷二磷酸核糖）聚合酶（PARP）抑制剂作为新诊断卵巢癌女性的维持治疗：系统评价和荟萃分析。
Arch Gynecol Obstet. 2021 Aug;304(2):285-296. doi: 10.1007/s00404-021-06070-2. Epub 2021 May 21.
6
Poly(ADP-ribose) polymerase (PARP) inhibitors for the treatment of ovarian cancer.聚（ADP-核糖）聚合酶（PARP）抑制剂治疗卵巢癌。
Cochrane Database Syst Rev. 2022 Feb 16;2(2):CD007929. doi: 10.1002/14651858.CD007929.pub4.
7
Benefit from maintenance with PARP inhibitor in newly diagnosed ovarian cancer according to BRCA1/2 mutation type and site: a multicenter real-world study.根据BRCA1/2突变类型和位点，新诊断卵巢癌患者使用PARP抑制剂维持治疗的获益：一项多中心真实世界研究
ESMO Open. 2025 Apr;10(4):104533. doi: 10.1016/j.esmoop.2025.104533. Epub 2025 Apr 1.
8
Risk-reducing bilateral salpingo-oophorectomy in women with BRCA1 or BRCA2 mutations.对携带BRCA1或BRCA2基因突变的女性进行降低风险的双侧输卵管卵巢切除术。
Cochrane Database Syst Rev. 2018 Aug 24;8(8):CD012464. doi: 10.1002/14651858.CD012464.pub2.
9
Evaluation of BRCA1/2 testing rates in epithelial ovarian cancer patients: lessons learned from real-world clinical data.上皮性卵巢癌患者中BRCA1/2检测率的评估：从真实世界临床数据中获得的经验教训。
Fam Cancer. 2025 May 5;24(2):43. doi: 10.1007/s10689-025-00467-7.
10
BRCA functional domains associated with high risk of multiple primary tumors and domain-related sensitivity to olaparib: the Prometheus Study.与多原发性肿瘤高风险相关的BRCA功能域及与奥拉帕利相关的结构域敏感性：普罗米修斯研究
ESMO Open. 2025 Feb;10(2):104076. doi: 10.1016/j.esmoop.2024.104076. Epub 2025 Jan 22.
引用本文的文献
1
Letter Re: Benefit from maintenance with PARP inhibitor in newly diagnosed ovarian cancer according To BRCA1/2 mutation type and site: a multicenter real-world study: Not all BRCA mutations are equal: functional context and mutation type as co-determinants of PARP inhibitor.信件回复：根据BRCA1/2突变类型和位点，新诊断卵巢癌患者使用PARP抑制剂维持治疗的获益：一项多中心真实世界研究：并非所有BRCA突变都是等同的：功能背景和突变类型作为PARP抑制剂的共同决定因素
ESMO Open. 2025 Jun;10(6):105298. doi: 10.1016/j.esmoop.2025.105298. Epub 2025 May 29.
2
Response to letter re: Benefit from maintenance with PARP inhibitor in newly diagnosed ovarian cancer according to BRCA1/2 mutation type and site: a multicenter real-world study: Not all BRCA mutations are equal: functional context and mutation type as co-determinants of PARP inhibitor response.对关于“根据BRCA1/2突变类型和位点，新诊断卵巢癌患者使用PARP抑制剂维持治疗的获益：一项多中心真实世界研究：并非所有BRCA突变都相同：功能背景和突变类型作为PARP抑制剂反应的共同决定因素”的信件的回复
ESMO Open. 2025 Jun;10(6):105299. doi: 10.1016/j.esmoop.2025.105299. Epub 2025 May 29.
3
Letter re: Benefit from maintenance with PARP inhibitor in newly diagnosed ovarian cancer according to BRCA1/2 mutation type and site: a multicenter real-world study: Ethnic difference in BRCT domain response to PARP inhibitor.信件回复：根据BRCA1/2突变类型和位点，新诊断卵巢癌患者使用PARP抑制剂维持治疗的获益：一项多中心真实世界研究：BRCT结构域对PARP抑制剂反应的种族差异
ESMO Open. 2025 Jun;10(6):105288. doi: 10.1016/j.esmoop.2025.105288. Epub 2025 May 27.
本文引用的文献
1
The Association Between Location of BRCA Mutation and Efficacy of PARP Inhibitor as a Frontline Maintenance Therapy in Advanced Epithelial Ovarian Cancer.BRCA突变位置与PARP抑制剂作为晚期上皮性卵巢癌一线维持治疗疗效之间的关联
Cancers (Basel). 2025 Feb 23;17(5):756. doi: 10.3390/cancers17050756.
2
Association of location of BRCA1 and BRCA2 mutations with benefit from olaparib and bevacizumab maintenance in high-grade ovarian cancer: phase III PAOLA-1/ENGOT-ov25 trial subgroup exploratory analysis.BRCA1 和 BRCA2 突变位置与奥拉帕利和贝伐珠单抗维持治疗高级别卵巢癌获益的相关性：III 期 PAOLA-1/ENGOT-ov25 试验亚组探索性分析。
Ann Oncol. 2023 Feb;34(2):152-162. doi: 10.1016/j.annonc.2022.11.003. Epub 2022 Nov 28.
3
Ethnic-specificity, evolution origin and deleteriousness of Asian BRCA variation revealed by over 7500 BRCA variants derived from Asian population.亚洲人群中超过 7500 个 BRCA 变异揭示了 BRCA 变异的种族特异性、进化起源和有害性。
Int J Cancer. 2023 Mar 15;152(6):1159-1173. doi: 10.1002/ijc.34359. Epub 2022 Nov 30.
4
Germline variation in BRCA1/2 is highly ethnic-specific: Evidence from over 30,000 Chinese hereditary breast and ovarian cancer patients.BRCA1/2 种系变异在不同种族间具有高度特异性：超过 30000 例中国遗传性乳腺癌和卵巢癌患者的证据。
Int J Cancer. 2019 Aug 15;145(4):962-973. doi: 10.1002/ijc.32176. Epub 2019 Feb 13.
Zotero 插件